Highlights: Montara Therapeutics awarded non-dilutive funding grant from The Michael J. Fox Foundation (MJFF) to advance a BrainOnlyâ„¢ therapy ...
Work at Trained Therapeutix Discovery Inc. has led to the development of new mammalian target of rapamycin (mTOR; FRAP1) inhibitors and high-density lipoprotein (HDL)-derived nanoparticles potentially ...
Galderma Holding SA has identified metabolites of CD-14547 acting as mammalian target of rapamycin (mTOR; FRAP1) inhibitors. As such, they are reported to be useful for the treatment of acne, atopic ...
BLU-222, an investigational, oral, potent, and highly selective CDK2 inhibitor (CDK2i), as monotherapy in patients (pts) with advanced solid tumors and in combination with ribociclib (RIBO) and ...
Managing the side effects in patients being treated for metastatic breast cancer can be challenging. Recently, Marla D. Lipsyc-Sharf, MD, a breast medical oncologist and health sciences clinical ...
The Milken Institute Science Philanthropy Accelerator for Research and Collaboration (SPARC), in partnership with the Ann Theodore Foundation (ATF), has launched a new funding program to support a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results